Product Description
Ki-67 may be considered as a valuable biomarker in breast cancer patients.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
I-share | N/A |
Recruiting |
Cervical Cancer|Uterine Cancer |
2027-02-01 |
|
ChiCTR2100054369 | N/A |
Recruiting |
Adenocarcinoma |
2023-12-31 |
|
ChiCTR2100054094 | N/A |
Recruiting |
Liver Cancer |
2023-12-01 |
|
ChiCTR2200055502 | N/A |
Recruiting |
Breast Cancer |
2022-12-31 |